November 2021 Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals, Inc The successful completion of this Phase 1 safety program will enable centers in Japan to be included

and Changes Name from ShouTi "San Francisco and Shanghai – August 1, 2022 – Structure Therapeutics Inc (Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an oversubscribed

uniform PK profile changes what co-administration cannot achieve How amino acid substitution within incretin The data is not incorrect. It is incomplete in a way the assay cannot disclose by design. steady-state observation would reveal only a progressive reduction in response as the ratio of antagonist increases

Kenakin joined Glaxo Inc in RTP where he remained for 25 years through iterations of Glaxo Inc, GlaxoWellcome

path from academic neuroendocrinology to introducing molecular biology and molecular pharmacology into Glaxo Foord is a physiologist and pharmacologist who spent more than two decades at Glaxo, Glaxo Wellcome, contributed to the identification of RAMPs in the CGRP receptor system, deorphanization of several GPCRs including and practical considerations in choosing receptor-rich tissues. 05:00 — Transition from academia to Glaxo

He spent 25 years in drug discovery at Glaxo (now GlaxoSmithKline) before joining UNC Chapel Hill, where with leading pharma and biotech companies. 1,500 human GPCR products covering ~90% of the GPCR-ome, including